Las tasas de discontinuacin del tratamiento debido a eventos adversos fueron del 8,7% y el 9,7% con orforglipron 12 mg y 36 mg , frente al 4,5% y el 4,9% con semaglutida oral en ACHIEVE-3
December 2023 Updates: SEPA: 2024 Large Group Quote Request Form Now Available For those prospecting in the Large Market space, the new Request forms included will be required during the RFP process for the applicable Highmark Region of South Eastern PA (SEPA) Enhanced capability of an eSignature has been added, for ease of completion
One study demonstrated that less than a third individuals achieved greater than 5% weight loss during the three-year study period and only 25% of these individuals were able to maintain greater than 5% weight loss
For many people, diet and exercise alone arent enough to achieve the results they want
Our personalized IV therapy can aid in reducing oxidative stress, improving energy levels, and supporting optimal wellness